Ondansetron As a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 18, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Injection Site Irritation
Interventions
DRUG

Ondansetron

Ondansetron (Zofran) is a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist commonly used to treat postoperative nausea and vomiting.

DRUG

Lidocaine

Lidocaine is a local anesthetic agent used intravenously prior to the propofol injection. Currently the standard of care to help decrease the severity of pain in the injection site, a common side effect of propofol.

Trial Locations (1)

30322

RECRUITING

Children's Healthcare of Atlanta, Atlanta

All Listed Sponsors
lead

Emory University

OTHER